Delcath HEPAZATO WKN: A2PT5P ISIN: US24661P8077 Kürzel: DCTH Forum: Aktien User: Standard

Zu Q3 https://investors.delcath.com/news-releases/news-release-details/delcath-systems-reports-third-quarter-2024-results-and-business Third Quarter and Recent Business Highlights Total third quarter revenues of $11.2 million, up 44% from the prior quarter, including $10.0 million from HEPZATO KIT™ (melphalan/Hepatic Delivery System) and $1.2 million from CHEMOSAT®; Activated four HEPZATO treatment centers in the U.S. during the third quarter and one more in October, bringing the total to twelve active centers; another center has scheduled their first treatment in November with a further 10 centers having partially or fully completed preceptorship training; Reported that CHOPIN, an investigator-initiated study which is evaluating the effect of sequencing immunotherapy with CHEMOSAT liver directed therapy, is now fully enrolled with 76 patients; Ended the third quarter with cash and investments of $14.0 million with quarterly cash burn of $3.6 million; and Subsequent to September 30, 2024: Submitted the final principal and interest payments of $2.8 million on the Rosalind note payable and as a result have no outstanding debt obligations; and All remaining Tranche B warrants from the March 29, 2023 PIPE were exercised by the November 6, 2024 expiration date resulting in approximately $25 million in proceeds.